美股异动 | 英伟达支持的AI制药公司Iambic Therapeutics(IAM.US)登陆纳斯达克 开盘后涨超11%

智通财经
Oct 16
【美股异动 | 英伟达支持的AI制药公司Iambic Therapeutics(IAM.US)登陆纳斯达克 开盘后涨超11%】智通财经APP获悉,周四,英伟达参股的AI制药公司Iambic Therapeutics(IAM.US)登陆纳斯达克,截至发稿,该股涨超11%,报17.77美元,触发交易所熔断机制。IPO价格为16美元。Iambic Therapeutics是一家临床阶段的生物技术公司,将专有AI模型与自动化高通量化学和生物学相结合,用于设计小分子药物。该平台运行一个闭环流程:其模型提出化合物方案,机器人实验室每周针对每个项目合成并测试数百种化合物,由此产生的数据再用于重新训练模型。其主要候选药物IAM1363是一种选择性、可穿透血脑屏障的HER2抑制剂,正在针对HER2改变的实体瘤开展1/1b期临床试验,最早可能于2027年启动注册性试验;另外两个靶向KIF18A和CDK2/4的临床前项目计划于第四季度提交IND申请。迄今为止,Iambic Therapeutics已通过与艾伯维(ABBV.US)、武田制药(TAK.US)、拜耳(BAYRY.US)等公司的合作获得收入。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10